ALT An illustration of chronic obstructive airway diseases showing human lungs. A proton pump inhibitor container is connected by an arrow to two magnified circles, depicting airway constriction and airway inflammation.

ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.

ALT A silhouette of a person with a highlighted stomach. A magnified view shows human epidermal growth factor receptor 2. To the side, medical supplies including two vials and an IV bag are displayed, representing zanidatamab plus tislelizumab plus chemotherapy.

ALT JAMA Cardiology Research Letter: Extended Low-Dose Apixaban and Superficial Vein Thrombosis: Post Hoc Analysis of the HI-PRO Randomized Clinical Trial. Two cumulative incidence curves compare Apixaban 2.5mg & Placebo for primary (P=.04) & secondary (P=.14) outcomes, showing lower event rates with Apixaban. Number at risk tables included.

ALT This image shows three Kaplan-Meier survival curves comparing talazoparib plus enzalutamide versus placebo plus enzalutamide across different subgroups over months. Each graph represents a different subgroup: Intention-to-Treat Population, BRCA Subgroup, and Non-BRCA Subgroup. The x-axis is in months, and the y-axis represents the percentage of patients. Data points are annotated with the number of events and median imaging-based progression-free survival times.

ALT A four-panel graph illustrating the secondary efficacy end points. Panel A shows overall survival, with a line graph comparing talazoparib–enzalutamide and placebo–enzalutamide over 56 months. Panel B displays a line graph of confirmed PSA progression. Panel C features a line graph detailing subsequent antineoplastic therapy. Panel D is a bar graph depicting the objective response, with categories for complete response, partial response, stable disease, and progression, comparing both treatment groups.